Publications by authors named "N Somaiah"
Aims: To establish the safety and feasibility of delivering neoadjuvant radiotherapy and endocrine therapy for oestrogen receptor-positive breast cancers with palpable size 20mm or greater, for which radiotherapy might facilitate more conservative surgery.
Materials And Methods: A single-arm feasibility study was conducted. Patients received whole breast radiotherapy with or without radiotherapy to nodal areas.
: The management of early breast cancer (BC) includes surgery, followed by adjuvant radiotherapy, chemotherapy, hormone therapy, or immunotherapy. However, the influence of these interventions in metabolic reprogramming remains unknown. This study explored alterations in the plasma metabolome of BC patients following distinct treatments to deepen our understanding of BC pathophysiology, outcomes, and the identification of potential biomarkers.
View Article and Find Full Text PDFArticle Synopsis
- KORTUC, a treatment combining hydrogen peroxide and sodium hyaluronate, shows promise in reducing hypoxic conditions in tumors after being injected directly into them, potentially improving cancer treatment outcomes.
- In tests using human tumor models, KORTUC led to a notable decrease in hypoxia markers and increased reactive oxygen species levels, indicating enhanced oxygen availability in cancerous tissues.
- If successful in ongoing clinical trials, KORTUC could transform radiation therapy for various cancers, particularly those where low oxygen levels limit treatment effectiveness.
Article Synopsis
- The study aimed to assess how baseline imaging parameters from F-18-fluorodeoxy-D-glucose PET/CT can predict treatment responses in patients with dedifferentiated and well-differentiated liposarcomas.
- A total of 24 patients were evaluated, with specific parameters like SUVmax, SUVmean, and Hounsfield units calculated from their PET and CT images to measure tumor response to systemic therapy.
- The research identified that new baseline SUV/HU ratios were effective indicators of treatment outcomes, suggesting changes in SUVmean may provide better insights than traditional metrics alone.
Background: The course of subclinical gastrointestinal stromal tumors (GISTs) is variable. The management of small GISTs is not well-defined.
Methods: Records of patients presenting with small GISTs with documented follow-up appointment at our institution between 2016 and 2022 were identified and reviewed.